Does sacubitril/valsartan reduce sNEP activity and alter natriuretic peptide metabolism in patients with chronic heart failure?
Sacubitril/valsartan exerts a pleiotropic favorable impact on the metabolism of heart failure patients, primarily affecting ANP rather than BNP.
Sacubitril/valsartan rapidly and strongly reduced sNEP activity, leading to an increase in levels of NEP substrates. These data suggest a pleiotropic favourable impact of sacubitril/valsartan on the metabolism of HF patients with ANP rather than BNP as major effectors amongst natriuretic peptides.
Nougue et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: